An underwritten offering of common stock involving a group of institutional investors, including Roche Finance, has been priced by Senseonics in hopes of raising $41 million. Net proceeds from the offering of 29 million shares will be used as working capital, as well as to support US commercialization of the Eversense continuous glucose monitor and research and development efforts for the device's next-generation versions.
Offering could pull in $41M for Senseonics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.